Effectiveness of the female condom in preventing HIV and sexually transmitted infections: a systematic review and meta-analysis
| Autor: | Charles Shey Wiysonge, Phetole Walter Mahasha, Alison B. Wiyeh, Ruth K. B. Mome, Eugene J Kongnyuy |
|---|---|
| Přispěvatelé: | Department of Public Health and Family Medicine, Faculty of Health Sciences |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Sexually Transmitted Diseases HIV Infections law.invention 03 medical and health sciences 0302 clinical medicine Female condom Condom law Internal medicine Epidemiology medicine Sexually transmitted infections Humans 030212 general & internal medicine Condoms Female Adverse effect Randomized Controlled Trials as Topic 030219 obstetrics & reproductive medicine Chlamydia business.industry Public health lcsh:Public aspects of medicine Public Health Environmental and Occupational Health virus diseases HIV lcsh:RA1-1270 medicine.disease Meta-analysis Systematic review Female Biostatistics business Research Article |
| Zdroj: | BMC Public Health BMC Public Health, Vol 20, Iss 1, Pp 1-17 (2020) |
| Popis: | Background The effectiveness of female condoms for preventing HIV and sexually transmitted infections (STIs) remains inconclusive. We examined the effects of female condoms on the acquisition of HIV and STIs. Methods We searched four databases, two trial registries, and reference lists of relevant publications in October 2018 and updated our search in February 2020. We screened search output, evaluated study eligibility, and extracted data in duplicate; resolving differences through discussion. We calculated the effective sample size of cluster randomised trials using an intra-cluster correlation coefficient of 0·03. Data from similar studies were combined in a meta-analysis. We performed a non-inferiority analysis of new condoms relative to marketed ones using a non-inferiority margin of 3%. We assessed the certainty of evidence using GRADE. Results We included fifteen studies of 6921 women. We found that polyurethane female condoms (FC1) plus male condoms may be as effective as male condoms only in reducing HIV acquisition (1 trial, n = 149 women, RR 0.07, 95%CI 0.00–1.38; low-certainty evidence). However, the use of FC1 plus male condoms is superior to male condoms alone in reducing the acquisition of gonorrhoea (2 trials, n = 790, RR 0.59, 95%CI 0.41–0.86; high-certainty evidence) and chlamydia (2 trials, n = 790, RR 0.67, 95%CI 0.47–0.94; high-certainty evidence). Adverse events and failure rates of FC1 were very low and decreased during follow up. Although the functionality of newer female condoms (Woman’s, Cupid, Pheonurse, Velvet, and Reddy) may be non-inferior to FC2, there were no available studies assessing their efficacy in preventing HIV and STIs. Conclusion The use of female plus male condoms is more effective than use of male condoms only in preventing STIs and may be as effective as the male condom only in preventing HIV. There is a need for well conducted studies assessing the effects of newer female condoms on HIV and STIs. PROSPERO registration number CRD42018090710 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|